Daxor Corporation reports developments tied to blood volume measurement technology, including commercialization of its FDA-cleared Blood Volume Analysis diagnostics and the BVA-100 Blood Volume Analyzer. Company news commonly covers clinical data, cardiology and critical-care use cases, new customer programs, conference presentations, and product updates for rapid, portable BVA systems.
Daxor also issues updates on financial results, shareholder communications, capital actions, and market expansion for its ezBVA Lab workflow and related diagnostic services. Its coverage centers on precision fluid management, heart failure, ICU care, and adoption of direct blood, plasma, and red-cell volume measurement in clinical settings.
Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, will exhibit at the American Association of Heart Failure Nurses 18th Annual Meeting from June 15-18, 2022, in Orlando, Florida. They aim to educate healthcare professionals on their blood volume technology, which reportedly reduces 30-day mortality by 82% and readmissions by 56%. Daxor has conducted over 60,000 tests across the U.S., contributing to better patient outcomes in various medical conditions, including heart failure.
Daxor Corporation (Nasdaq: DXR) announced its participation in a National Institutes of Health (NIH) study on neurologic function after COVID-19 infection, utilizing its BVA-100 technology. Led by Dr. Avindra Nath at the NIH's National Institute of Neurological Disorders and Stroke, the study aims to address lingering symptoms from COVID-19, such as 'brain fog.' CEO Michael Feldschuh highlighted the clinical utility of the BVA-100, which is commonly used in hospitals. Daxor is also developing a next-generation portable analyzer under contract with the Department of Defense.
Daxor Corporation (Nasdaq: DXR) will present at the H.C. Wainwright Global Life Investment Hybrid Conference from May 23-26, 2022, in Miami Beach, FL. CEO Michael Feldschuh will speak on May 25 at 4:30 PM ET, highlighting the company's achievements in financial performance, product commercialization, and collaborations with the U.S. Department of Defense and the National Institute of Health. Daxor's BVA-100® blood test is pivotal in managing critical care, COVID-19, and heart failure, with over 60,000 tests conducted. Interested parties can register for the event and request one-on-one meetings.
Daxor Corporation (Nasdaq: DXR) has presented new data at the ISHLT Annual Meeting showcasing the efficacy of its BVA-100 blood test in enhancing survival rates for advanced heart failure patients using LVADs. The study revealed that 91% of patients with LVADs exhibited abnormal blood volume, indicating the test's critical role in patient management. With a 98% accuracy rate, the BVA-100 test helps identify derangements in blood volume, potentially improving patient outcomes. Daxor emphasizes its commitment to advancing healthcare through blood volume analysis technology.
Daxor Corporation (Nasdaq: DXR) presented new data from a study at the 71st American College of Cardiology meeting on April 2, revealing the effectiveness of the BVA-100 test in measuring intravascular congestion in heart failure patients. This test outperformed common clinical tools, which were found ineffective. The study led by Dr. Vishal N. Rao emphasized that blood volume measurements do not correlate with cardiac pressures, indicating the superiority of Daxor's approach in improving patient outcomes in heart failure management.
Daxor Corporation (Nasdaq: DXR) announced that CEO Michael Feldschuh will present at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. The presentation will cover recent achievements, including contracts with the U.S. Department of Defense, NIH grant funding, and clinical trials for its BVA-100® blood test aimed at critical care management, COVID-19, and heart failure. Registration is required to attend the conference and view the presentation.
Daxor Corporation (Nasdaq: DXR) reported significant achievements in its recent shareholder update. On February 4, 2022, Daxor celebrated its Nasdaq listing with a ceremonial bell ringing in Times Square. The company achieved a 70.6% revenue increase in 2021 compared to the previous year, reporting a net asset value of $21.15 million. Daxor plans to launch new point-of-care blood volume systems in 2022, enhancing market capabilities. The company also made strides in clinical outcomes and research with NIH support, marking a pivotal year for growth and innovation.
Daxor Corporation (Nasdaq: DXR) reported impressive financial results for fiscal 2021, achieving a 70.6% increase in unaudited revenues from its operating division, which includes the BVA diagnostic systems. The company's net asset value (NAV) rose to $5.24 per share, marking a 34.7% increase from $3.89 in 2020. The growth is attributed to new client contracts, including the U.S. Department of Defense. Daxor also announced advancements in its next-generation blood volume analysis technology and secured a $750,000 contract for further development.
Daxor Corporation (Nasdaq: DXR) has revealed new data on the clinical utility of its BVA-100 blood test for heart failure patients, published in the Journal of Cardiac Failure. The study indicates a disconnect between pressure and blood volume metrics, emphasizing the importance of blood volume assessment over pressure monitoring in managing heart failure. Authors noted that volume-based strategies may enhance patient care. With over 100 peer-reviewed studies supporting its efficacy, Daxor's technology is positioned as a critical tool in addressing heart volume management.
Daxor Corporation (Nasdaq: DXR) commenced trading on the NASDAQ Capital Markets on February 2, 2022. To celebrate, CEO Michael Feldschuh will ring the Opening Bell on February 4, 2022. This milestone is expected to enhance the company's visibility, trading liquidity, and attract institutional investors. Daxor specializes in blood volume measurement technology, with over 60,000 tests conducted using their FDA-cleared BVA-100. Ongoing trials in heart failure and COVID-19 are supported by the NIH and the Department of Defense.